



15th World Congress on

BIO-TECHNOLOGY AND BIO-TECH INDUSTRIAL MEETINGS
&

2nd International Conference on

ENVIRONMENTAL AND MOLECULAR BIOLOGY

March 20-21, 2017 Rome, Italy

AvidinOX-targeted delivery: A new way to improve efficacy of well-known monoclonal antibodies for cancer therapy

We recently discovered that the oxidized version of hen egg white avidin, named AvidinOX, can chemically link to tissue proteins when injected or nebulized, thus becoming an artificial receptor for biotinylated therapeutics. This product is currently under investigation in phase I clinical trials for targeting intravenously administered ¹⁷⁷Lutetium-biotinDOTA to inoperable tumor lesions and liver metastases, pre-injected with AvidinOX (ClinicalTrials.gov NCT02053324). Several published and some non-published data from our group indicate that AvidinOX-targeted delivery of the biotinylated version of some marketed monoclonal antibodies turns non-effective doses of such antibodies effective for cancer treatment. Among the antibodies tested, AvidinOX-targeted delivery of biotinylated anti-EGFR cetuximab and panitumumab, and anti-*ErbB2/neu*

Notes: